In the GRADUATE I (NCT03444870, n = 1053) and GRADUATE II (NCT03443973, n = 975) studies of patients with early AD, gantenerumab failed to demonstrate a significant clinical benefit, with CDR-SB differences of only −0.31 and −0.19 compared with the placebo, despite robust reductions in amyloid plaques and improvements in CSF biomarkers, including total tau, p-tau181, and neurogranin [33]. Here, MAPT is linked to Alzheimer disease.